Medigen Biotechnology Corp. (TPEX:3176)

Market Cap	4.97B
Revenue (ttm)	1.41B
Net Income (ttm)	-412.89M
Shares Out	139.31M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,804
Average Volume	299,495
Open	35.60
Previous Close	35.60
Day's Range	35.50 - 36.15
52-Week Range	29.50 - 48.20
Beta	0.58
RSI	58.07
Earnings Date	Mar 28, 2025

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2023, Medigen Biotechnology's revenue was 1.16 billion, an increase of 9.64% compared to the previous year's 1.06 billion. Losses were -561.30 million, -16.95% less than in 2022.